Search results
Earnings call: Kura Oncology reports on ziftomenib's progress By Investing.com
Investing.com· 7 days agoZiftomenib has received Breakthrough Therapy designation from the FDA for the treatment of...
Curis to Present Updated Data from the TakeAim Leukemia Study
WPRI Providence· 3 days ago(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present ...
Danbury High runner who was on death bed with cancer graduates from Sacred Heart: 'Very determined'
The News-Times· 2 days agoIn May 2019, 21-year-old Alex Chakar was diagnosed with acute myeloid leukemia and within a few...
Red carpet with a cause: This fashion show fundraiser helps kids with cancer
The Record· 4 days agoIt is now a life purpose for Paula Corrieri, of Wayne, whose 15-year-old son, Rocco Sivolella, died...
Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday
ETF DAILY NEWS· 1 day agoSyros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, May 14th. Analysts expect Syros Pharmaceuticals to post earnings ...
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
Morningstar· 7 days agoTC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today ...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio,...
Benzinga· 15 hours agoNEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ:BLUE). Such investors are advised to
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Yucaipa News Mirror· 6 days agoFirst quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 millionExpanded Rigel's portfolio with acquisition of
2 Incredible Growth Stocks to Buy Hand Over Fist
Motley Fool via Yahoo Finance· 5 days agoThis novel oral treatment for leukemia has the potential to surpass $1 billion in sales if it secures regulatory nods in both the front- and later-line...
Apollomics shares target cut on Phase 3 study results By Investing.com
Investing.com· 5 days agoThe adjustment came in response to recently revealed Phase 3 study results which did not meet the...